Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

• Status: Active, not recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Treatments: Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Etoposide phosphate; Hydrocortisone; Liposomal doxorubicin; Mechlorethamine; Nitrogen Mustard Compounds; Prednisone; Vinblastine; Vincristine

Criteria

Inclusion Criteria:

• Patient is less than or equal to 21 years of age

• Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma

• Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal involvement (3 or more sites), or bulky mediastinal adenopathy.

Exclusion Criteria:

• Patients with favorable risk features

• Patients with unfavorable risk features

• Patients who have received prior therapy for Hodgkin lymphoma.